Literature DB >> 24639712

Anti-mullerian and androgens hormones in women with polycystic ovary syndrome undergoing IVF/ICSI.

Menha Swellam1, Abeer Khaial2, Tamer Mosa1, Hatim El-Baz3, Mohamed Said4.   

Abstract

BACKGROUND: Despite its frequency, the polycystic ovary syndrome (PCOS) is still a difficult diagnosis in endocrinology, gynecology, and reproductive medicine. The Rotterdam consensus conference proposed to include the ultrasonographic follicle count as a new diagnostic criterion. Unfortunately, its assessment does not offer sufficient reliability worldwide.
OBJECTIVE: To explore the possible roles of altered circulating androgens and anti-mullerian hormone among PCOS women regarding their body mass index and their outcomes after IVF.
MATERIALS AND METHODS: In this cross sectional study, 195 women with PCO were included, they were divided according to their body mass index (BMI <27 kg/m(2)) as obese PCOS (n=91) and overweight PCOS (BMI ≥27 kg/m(2)) (n=104). Serum levels of androgens (dehydroepiandrosterone sulfate [DHEAS], testosterone and androstenedione [A4]), and anti-mullerian hormone (AMH) were assessed and compared with the endocrine profile and cycles outcomes.
RESULTS: AMH, A4, FSH, and TSH concentrations were significantly higher in obese than in overweight women (p˂0.001). Contrary, LH: FSH ratio values, E2, PRL and DAHE-S levels were significantly lower in obese than in overweight women (p˂0.0001). Total oocyte retrieved, mature and fertilized oocyte were significantly higher in obese than in overweight women. Among pregnant obese PCOS women both AMH and A4 were significantly increased and DAHE-S was significantly decreased compared to pregnant overweight PCOS women.
CONCLUSION: Obese PCOS women have a higher chance of getting pregnant over those categorized as overweight PCOS. Also, androgens and AMH levels recommended to be considered in IVF attributes among obese and overweight PCOS women.

Entities:  

Keywords:  Androgen hormone; Androstenedione; Anti-mullerian hormone; Polycystic ovary syndrome

Year:  2013        PMID: 24639712      PMCID: PMC3941393     

Source DB:  PubMed          Journal:  Iran J Reprod Med        ISSN: 1680-6433


  15 in total

1.  Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline.

Authors:  Ricardo Azziz; Enrico Carmina; Didier Dewailly; Evanthia Diamanti-Kandarakis; Hector F Escobar-Morreale; Walter Futterweit; Onno E Janssen; Richard S Legro; Robert J Norman; Ann E Taylor; Selma F Witchel
Journal:  J Clin Endocrinol Metab       Date:  2006-08-29       Impact factor: 5.958

2.  Serum luteinizing hormone levels are markedly increased and significantly correlated with Delta 4-androstenedione levels in lean women with polycystic ovary syndrome.

Authors:  Dimitrios Panidis; Dimitrios Farmakiotis; David Rousso; Ilias Katsikis; Anargyros Kourtis; Evanthia Diamanti-Kandarakis
Journal:  Fertil Steril       Date:  2005-08       Impact factor: 7.329

3.  Determining the normal cut-off levels for hyperandrogenemia in Chinese women of reproductive age.

Authors:  Xiaomiao Zhao; Zehui He; Yaqin Mo; Xiaoli Chen; Yaxiao Chen; Dongzi Yang
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2010-12-15       Impact factor: 2.435

4.  Anti-Müllerian hormone inhibits initiation of primordial follicle growth in the mouse ovary.

Authors:  Alexandra L L Durlinger; Maria J G Gruijters; Piet Kramer; Bas Karels; Holly A Ingraham; Mark W Nachtigal; Jan Th J Uilenbroek; J Anton Grootegoed; Axel P N Themmen
Journal:  Endocrinology       Date:  2002-03       Impact factor: 4.736

Review 5.  The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report.

Authors:  Ricardo Azziz; Enrico Carmina; Didier Dewailly; Evanthia Diamanti-Kandarakis; Héctor F Escobar-Morreale; Walter Futterweit; Onno E Janssen; Richard S Legro; Robert J Norman; Ann E Taylor; Selma F Witchel
Journal:  Fertil Steril       Date:  2008-10-23       Impact factor: 7.329

Review 6.  Polycystic ovary syndrome: pathogenesis and treatment over the short and long term.

Authors:  Theresa L Marx; Adi E Mehta
Journal:  Cleve Clin J Med       Date:  2003-01       Impact factor: 2.321

7.  Anti-Müllerian hormone serum concentrations in normoovulatory and anovulatory women of reproductive age.

Authors:  Joop S E Laven; Annemarie G M G J Mulders; Jenny A Visser; Axel P Themmen; Frank H De Jong; Bart C J M Fauser
Journal:  J Clin Endocrinol Metab       Date:  2004-01       Impact factor: 5.958

8.  Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome.

Authors: 
Journal:  Fertil Steril       Date:  2004-01       Impact factor: 7.329

9.  Anti-Müllerian hormone concentrations in androgen-suppressed women with polycystic ovary syndrome.

Authors:  S M Carlsen; E Vanky; R Fleming
Journal:  Hum Reprod       Date:  2009-04-02       Impact factor: 6.918

10.  Anti-Mullerian hormone is increased in follicular fluid from unstimulated ovaries in women with polycystic ovary syndrome.

Authors:  M Das; D J Gillott; E Saridogan; O Djahanbakhch
Journal:  Hum Reprod       Date:  2008-06-10       Impact factor: 6.918

View more
  5 in total

1.  Demographic, lifestyle, and other factors in relation to antimüllerian hormone levels in mostly late premenopausal women.

Authors:  Seungyoun Jung; Naomi Allen; Alan A Arslan; Laura Baglietto; Louise A Brinton; Brian L Egleston; Roni Falk; Renée T Fortner; Kathy J Helzlsouer; Annika Idahl; Rudolph Kaaks; Eva Lundin; Melissa Merritt; Charlotte Onland-Moret; Sabina Rinaldi; María-José Sánchez; Sabina Sieri; Helena Schock; Xiao-Ou Shu; Patrick M Sluss; Paul N Staats; Ruth C Travis; Anne Tjønneland; Antonia Trichopoulou; Shelley Tworoger; Kala Visvanathan; Vittorio Krogh; Elisabete Weiderpass; Anne Zeleniuch-Jacquotte; Wei Zheng; Joanne F Dorgan
Journal:  Fertil Steril       Date:  2017-04       Impact factor: 7.329

2.  Anti-mullerian hormon level and polycystic ovarian syndrome diagnosis.

Authors:  Shahrzad Zadehmodarres; Zahra Heidar; Zahra Razzaghi; Leili Ebrahimi; Kaveh Soltanzadeh; Farhang Abed
Journal:  Iran J Reprod Med       Date:  2015-04

3.  Comparison of Specificity and Sensitivity of AMH and FSH in Diagnosis of Premature Ovarian Failure.

Authors:  Farzaneh Alipour; Athar Rasekhjahromi; Mehrnoosh Maalhagh; Saeid Sobhanian; Masoumeh Hosseinpoor
Journal:  Dis Markers       Date:  2015-05-31       Impact factor: 3.434

Review 4.  Maximizing the clinical utility of antimüllerian hormone testing in women's health.

Authors:  Benjamin Leader; Valerie L Baker
Journal:  Curr Opin Obstet Gynecol       Date:  2014-08       Impact factor: 1.927

5.  Relationship between Serum Levels of Anti-Mullerian Hormone, Adiponectin and Oxidative Stress Markers in Patients with Polycystic Ovary Syndrome.

Authors:  Mozhgan Kohzadi; Mohammad Rasool Khazaei; Farzaneh Choobsaz; Mozafar Khazaei
Journal:  Int J Fertil Steril       Date:  2020-02-25
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.